Skip to Content

'
Agop Y. Bedikian, M.D.

Present Title & Affiliation

Primary Appointment

Professor And Deputy Director of the Skin Center, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Internist, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1971 American University of Beirut, Beirut, Lebanon, MD, Medicine
1967 University of Beirut, N/A, Lebanon, BS, Bachelor of Science

Postgraduate Training

1975-1977 Clinical Fellowship, Medical Oncology, The University of Texas System Cancer Center, Houston, TX
1973-1975 Clinical Residency, Oncology, Barnes Hospital, St. Louis, MO

Board Certifications

6/1979 American Board of Medical Oncology
6/1977 American Board of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs 32(2):279-86, 4/2014. e-Pub 6/12/2013. PMID: 23756764.
2. Kolandjian NA, Wei C, Patel SP, Richard JL, Dett T, Papadopoulos NE, Bedikian AY. Delayed Systemic Recurrence of Uveal Melanoma. Am J Clin Oncol 36(5):443-9, 10/2013. e-Pub 6/14/2012. PMID: 22706174.
3. Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination. J Immunother 36(4):276-86, 5/2013. PMCID: PMC3799876.
4. Radvanyi LG, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, Wu RC, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson V, McMannis JD, Shpall EJ, Prieto VG, Papadopoulos NE, Kim KB, Homsi J, Bedikian AY, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. e-Pub 10/2/2012. PMID: 23032743.
5. Noor R, Bedikian AY, Mahoney S, Bassett R, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer 20(10):2583-8, 10/2012. e-Pub 1/25/2012. PMID: 22274951.
6. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. e-Pub 7/19/2012. PMID: 22809251.
7. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res. e-Pub 6/2/2012. PMID: 22668797.
8. Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. e-Pub 5/2012. PMID: 22584956.
9. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng C, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. e-Pub 1/5/2012. PMID: 22223528.
10. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res 21(4):357-63, 8/2011. PMCID: PMC3132394.
11. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. Clin Cancer Res 15(17):4882-91, 7/2011. e-Pub 6/2011. PMID: 21632855.
12. Kolandjian NA, Patel SP, Papadopoulos NE, Bedikian AY. The left ventricle as the first site of uveal melanoma metastasis 13 years after treatment of the primary tumor. Melanoma Res. e-Pub 2/2011. PMID: 21346640.
13. Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest 29(1):49-55, 1/2011. PMID: 21166498.
14. Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res. e-Pub 12/16/2010. PMID: 21169870.
15. Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res 20(6):507-510, 12/2010. e-Pub 9/2010. PMID: 20881508.
16. Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res 20(6):501-506, 12/2010. e-Pub 9/2010. PMID: 20859231.
17. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P. Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. Am J Clin Oncol - Canc. e-Pub 12/2010. PMID: 21150567.
18. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. e-Pub 11/22/2010. PMID: 21102360.
19. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemoth Pharm 66(6):1087-93, 11/2010. e-Pub 3/2010. PMID: 20204368.
20. Bedikian AY, Silverman JA, Papodopolous NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P. Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function. J Clin Pharmacol. e-Pub 10/26/2010. PMID: 20978276.
21. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver: Response, Survival, and Prognostic Factors. Am J Clin Oncol - Canc 33(5):474-80, 10/2010. e-Pub 11/2009. PMID: 19935383.
22. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer - Am Cancer Soc. e-Pub 10/2010. PMID: 20960525.
23. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer - Am Cancer Soc 116(17):4086-94, 9/2010. PMCID: PMC2930110.
24. Bedikian AY, DeConti RC, Agarwala S, Papadopuolos N, Ernstoff M. Phase 3 Study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. e-Pub 9/2010. PMID: 20855467.
25. Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R. A phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20(3):218-226, 6/2010. e-Pub 3/2010. PMID: 20354459.
26. Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY, Hwu P. GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res 20(3):184-90, 6/2010. PMID: 20375921.
27. Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L, Kirkwood JM. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), +/- dacarbazine in patients with stage IV metastatic melanoma. Cancer - Am Cancer Soc 116(6):1526-34, March 15, 2010, 3/2010. e-Pub 1/2010. PMID: 20108344.
28. Yoon C, Papadopoulos NE, Camacho LH, McIntyre S, Alvarado GC, Bedikian AY, Hwu P, Kim KB. The Clinical Efficacy of Combination of Docetaxel and Temozolomide in Previously Treated Patients with Stage IV Melanoma. Melanoma Res 20(1):43-47, 2/2010. e-Pub 12/2009. PMID: 19952963.
29. Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96)in patients with metastatic melanoma. J Transl Med 29:8-9, 1/2010. PMID: 20109236.
30. Glaspy J, Atkins MB, Richards JM, Agarwala SS, O’Day S, Knight RD, Jungnelius JU, Bedikian AY. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer - Am Cancer Soc:1-9, www.interscience.wiley.com, 11/2009.
31. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 27(7):756-63, 8/2009. PMID: 19440934.
32. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL. Hwu P. Phase 2 open-label study of weekly docosabexaenoic acid-paclitasel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 19(4):238-42, 8/2009. e-Pub 6/2009. PMID: 19521262.
33. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AMM. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 45(10):1807-14, 7/2009. e-Pub 5/2009. PMID: 19419855.
34. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol - Canc. e-Pub 6/2009. PMID: 19506454.

Invited Articles

1. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int'l Ophthalmol Clin 46(1):151-166, 2006.

Book Chapters

1. McGary EC, Bedikian AY, Rapini RP. Malignant Melanoma: Biology, Diagnosis and Management. Chapter M. D. Anderson Manual of Medical Oncology. In: The M.D. Anderson Manual of Medical Oncology. 32. McGraw-Hill: New York, NY, 855-877, 2006.

Grant & Contract Support

Title: Phase II Trial of ABI-007 (Abraxane) and Ipilimumab in Patients with Metastic Melanoma, 2011-1157
Funding Source: Celgene Corporation
Role: Principal Investigator
Duration: 1/9/2013 - 1/8/2016
 
Title: Phase II Study of IPILIMUMAB plus Temozolomide in Patietns with Metastatic Melanoma
Funding Source: Bristol-Myers Squibb
Role: Principal Investigator
Duration: 4/19/2010 - 4/19/2011
 
Title: A Phase II CT study of tesetaxel as second-line therapy for subjects with advanced melnaoma and normal serum LDH
Funding Source: Genta Incorporated
Role: Principal Investigator
Duration: 2/3/2010 - 2/28/2012
 
Title: A Phase 1/2 Open-Label Study of TPI 287 in combination with Temozolomide for Patients with Metastatic Melanoma
Funding Source: Archer Biosciences, Inc.
Role: Principal Investigator
Duration: 1/14/2010 - 1/31/2012
 
Title: Phase I Study of Weekly LOC-paclitaxel Injections
Funding Source: Luitpold Pharmaceuticals, Inc.
Role: Principal Investigator
Duration: 11/10/2009 - 11/30/2015
 
Title: A Phase II Multicenter Open Label Study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma
Funding Source: Astellas Pharma US, Inc.
Role: Principal Investigator
Duration: 10/26/2009 - 10/31/2011
 
Title: Phase I/II Study of Hepatic Arterial Infusion of Abraxane in Patients with Metastatic Melanoma in the Liver
Funding Source: Abraxis Oncology
Role: Principal Investigator
Duration: 10/27/2008 - 10/31/2011
 
Title: Phase II Randomized, Open-Label Study of IMC-1121B with or without Dacarbazine in Patients with Metastatic Malignant Melanoma
Funding Source: ImClone Systems
Role: Principal Investigator
Duration: 2/14/2008 - 2/28/2011
 
Title: A Multicenter, Randomized, Double-Blind Study of Dacarzabine with or without Genasense in Chemotherapy-Naive Subjects with Advanced Melanoma and Low LDH
Funding Source: Genta, Inc.
Role: Principal Investigator
Duration: 7/19/2007 - 7/31/2011
 
Title: A Phase II Study of MARQIBO in Patients with Metastatic Choroidal Melanoma
Funding Source: Hana Biosciences
Role: Principal Investigator
Duration: 2/15/2007 - 2/28/2012

Last updated: 11/22/2013